Boston Scientific Hooks In Millipede, But Still Trailing Behind In Mitral Valve Race

Boston Scientific is pumping money into the high-potential mitral valve repair space by making a strategic investment in Millipede, as well as signing an acquisition option agreement that could be worth nearly half a billion dollars. However, its cardiovascular rivals are already some distance ahead in this space.

Playing catch-up to its other cardiovascular device rivals, Boston Scientific Corp. is investing in the mitral valve repair space by putting money into Millipede, a California start-up that has developed the IRIS transcatheter annuloplasty ring system.

Boston Scientific paid $90m for a stake in Santa Rosa-based Millipede. Additionally, the cardiovascular company has taken an option to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

More from Device Area